**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 61-year-old woman and a 51-year-old woman developed asymptomatic SARS-CoV-2 infection during treatment with carboplatin, paclitaxel or plicamycin \[*routes, dosages and outcomes not stated*\].

Case 1: The 61-year-old woman was diagnosed with advanced ovarian cancer with metastases, underwent treatment with cytoreductive surgery and unspecified chemotherapy. On 5 October 2019, she was initiated on first-line chemotherapy with carboplatin and paclitaxel; she received 5 cycles of the therapy. After the lockdown in Wuhan, China, she experienced a delay in treatment. On 10 February 2020, she reported dry cough without symptoms of nausea, diarrhoea, fever, myalgia or vomiting. She was then hospitalised for second-line chemotherapy with liposomal plicamycin [1](#Fn1){ref-type="fn"} and received one cycle. On 21 March 2020, she showed positive results upon a COVID-19 screening. However, her IgM, PCR analysis of a throat swab and CT scan were all negative. She eventually developed grade 4 thrombocytopenia secondary to the chemotherapy. She was treated with supportive therapy of elevating platelets. She was confirmed to have been an asymptomatic carrier of SARS-CoV-2.

Case 2: The 51-year-old woman was diagnosed with cervical squamous cell carcinoma. On 24 November 2019, she was initiated on treatment with paclitaxel and carboplatin, which she received for 3 cycles. Her treatment was interrupted due to the lockdown in Wuhan, China. On 14 February 2020, she reported mild fatigue, which resolved within one day. On 22 March 2020, screening was positive for COVID-19. However, her CT scan and PCR analysis of throat swabs was negative. She subsequently underwent pelvic radiation. She was confirmed to have been an asymptomatic carrier of SARS-CoV-2.

Plicamycin was wrongly spelled as epicamycin in the article.
